Dianthus Therapeutics (NASDAQ:DNTH) Director Anne Mcgeorge Sells 7,750 Shares of Stock

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Director Anne Mcgeorge sold 7,750 shares of Dianthus Therapeutics stock in a transaction on Monday, August 10th. The stock was sold at an average price of $109.01, for a total transaction of $844,827.50. Following the transaction, the director owned 1,250 shares in the company, valued at approximately $136,262.50. This trade represents a 86.11% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

Dianthus Therapeutics Stock Down 3.0%

Shares of Dianthus Therapeutics stock opened at $108.49 on Wednesday. The stock has a market cap of $5.93 billion, a price-to-earnings ratio of -26.14 and a beta of 1.22. Dianthus Therapeutics, Inc. has a twelve month low of $19.00 and a twelve month high of $114.55. The company’s fifty day moving average is $95.71 and its 200 day moving average is $81.79.

Dianthus Therapeutics (NASDAQ:DNTH) last announced its earnings results on Tuesday, August 4th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.85) by ($0.05). The company had revenue of $0.76 million for the quarter, compared to the consensus estimate of $0.30 million. Dianthus Therapeutics had a negative return on equity of 22.53% and a negative net margin of 10,096.95%. As a group, equities analysts anticipate that Dianthus Therapeutics, Inc. will post -3.83 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Dianthus Therapeutics

Institutional investors have recently added to or reduced their stakes in the business. Raymond James Financial Inc. bought a new stake in shares of Dianthus Therapeutics in the 2nd quarter valued at $27,000. First Horizon Corp bought a new position in Dianthus Therapeutics during the first quarter worth $32,000. Caitong International Asset Management Co. Ltd acquired a new stake in Dianthus Therapeutics in the fourth quarter worth $40,000. Russell Investments Group Ltd. acquired a new stake in Dianthus Therapeutics in the third quarter worth $64,000. Finally, Tower Research Capital LLC TRC increased its stake in Dianthus Therapeutics by 330.7% in the second quarter. Tower Research Capital LLC TRC now owns 4,320 shares of the company’s stock valued at $80,000 after purchasing an additional 3,317 shares in the last quarter. 47.53% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

DNTH has been the topic of a number of recent analyst reports. HC Wainwright lifted their price objective on Dianthus Therapeutics from $130.00 to $158.00 and gave the stock a “buy” rating in a research note on Thursday, August 6th. Wolfe Research reissued an “outperform” rating on shares of Dianthus Therapeutics in a research report on Wednesday, June 10th. Wall Street Zen upgraded shares of Dianthus Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, May 9th. Truist Financial boosted their price target on shares of Dianthus Therapeutics from $110.00 to $128.00 and gave the stock a “buy” rating in a research report on Thursday, August 6th. Finally, Raymond James Financial reaffirmed a “strong-buy” rating and issued a $131.00 price objective on shares of Dianthus Therapeutics in a research note on Wednesday, August 5th. One research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Dianthus Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $124.27.

Trending Headlines about Dianthus Therapeutics

Here are the key news stories impacting Dianthus Therapeutics this week:

• Positive Sentiment: HC Wainwright issued an optimistic estimate for Dianthus Therapeutics’ earnings, offering a potential bullish catalyst for DNTH. However, the report did not provide specific revised earnings targets. HC Wainwright Issues Optimistic Estimate for DNTH Earnings
• Neutral Sentiment: Reported short interest was zero shares as of August 11, unchanged from the prior reporting period, with a days-to-cover ratio of zero. This indicates little evidence of active short-selling pressure or a potential short squeeze in DNTH.
• Negative Sentiment: Several insiders sold shares around $109 to $111. Senior Vice President Adam M. Veness sold 20,000 shares across transactions on August 7 and August 10 for approximately $2.21 million, reducing his position by roughly 80.8% overall. SEC insider trading filing
• Negative Sentiment: Director Simon Read sold 2,777 shares for about $304,000, cutting his holdings by 50%. Director Anne McGeorge sold 7,750 shares for approximately $845,000, reducing her position by about 86%. The timing and size of these sales could raise concerns because they occurred while the stock was trading near its 12-month high. SEC director trading filing

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.